EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sansure Biotech Inc (688289) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Sansure Biotech Inc ¥15.88, price ¥16.57, upside -4.2%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CN · ISIN CNE1000043J1

SB Some data Sep 24, 2026

Sansure Biotech Inc

688289 · SHG

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value ¥15.88 · Fairly valued (−4%)
!Quality 55/100
!Weak Growth (revenue 5y −19.1 %/yr)
!Thin margins · 9.8% net margin (TTM)
!Low debt · negative free cash flow
·3.16% dividend yield
!Trails peers (5/13)
!Narrow moat 37/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 28 out of 100
!Weak on past: 6 out of 100
Watch Sansure Biotech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥61.25 ¥13.66 Fair Value ¥15.88 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥13.66 – ¥61.25 · fair‑value band ¥15.88 – ¥17.79 · the ¥16.57 price screens above the ¥15.88 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Sansure Biotech in your weekly email

Every Wednesday you see whether Sansure Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally.

Show more

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; and diagnostic kits for monkeypox, epstein-barr virus, and human cytomegalovirus DNA, as well as rapid antigen tests. The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems. In addition, it engages in the research and development, production, and sale of drugs; procurement and sale of raw materials; manufacture of instruments; manufacture and sale of electronic equipment; trading; investment consulting; medical research and experimental development; and internet sales, as well as offers third-party medical testing and biotechnology development services. The company was founded in 2008 and is headquartered in Changsha, China.

Stock analysis

Sansure Biotech Inc (688289) currently trades at ¥16.57, while our model-based Fair Value estimate is ¥15.88, implying the stock looks roughly 4.4% fairly valued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ¥15.89 per share, and 0 of the 17 models we run sit above the ¥16.57 price.

Bear case: the Dividend Discount group reads lowest at ¥7.37, and 17 of the 17 models stay below the price. Evidence for this calculation is medium.

Scenario range: ¥15.88 (bear) to ¥17.79 (bull), the price of ¥16.57 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Sansure Biotech Inc reported revenue of 1.6B CNY in FY2025 versus 4.5B CNY in FY2021, a compound −22.3%/yr. Reported net income was 198M CNY in FY2025, compounding −45.5%/yr from FY2021.

Key figures

Market cap 9.7B CNY (≈ $1.4B) · P/E ratio 63.7 · P/S ratio 7.66 · EPS (TTM) ¥0.2600 · Dividend yield 3.2% · Net margin 12.0% · Return on equity 1.6% · Return on assets (EBIT) 14.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −4%, 688289 screens cheaper than that median.

Fair Value models

Bear ¥15.88 Fair Value ¥15.88 Bull ¥17.79
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings ¥6.54 ¥7.99 ¥10.69 76
EPV ¥7.70 ¥8.04 ¥8.33 74
Residual Income ¥8.52 ¥8.20 ¥6.42 74
All 17 models by family
DCF Models
Owner Earnings ¥6.54 ¥7.99 ¥10.69 76
Earnings-Based
Graham-Dodd ¥2.33 ¥16.22 ¥22.76 61
Lynch FV ¥8.38 ¥11.97 ¥15.56 59
PEG = 1.0 ¥8.38 ¥11.97 ¥15.56 55
EPV ¥7.70 ¥8.04 ¥8.33 74
Dividend Discount
Gordon GGM ¥4.47 ¥8.06 ¥11.10 66
DDM Multi-Stage ¥4.47 ¥7.37 ¥8.61 65
Multiples
P/E Multiple ¥5.64 ¥7.52 ¥9.40 63
P/S Multiple ¥4.36 ¥5.81 ¥7.27 58
P/B Multiple ¥4.36 ¥5.81 ¥7.27 55
EV/EBIT ¥9.64 ¥11.12 ¥12.61 66
EV/EBITDA ¥12.68 ¥15.18 ¥17.69 67
EV/Revenue ¥8.36 ¥9.72 ¥11.09 54
Asset-Based
NCAV (Graham) ¥6.23 ¥8.35 ¥12.46 54
Economic Profit
Residual Income ¥8.52 ¥8.20 ¥6.42 74
ROIC Compounder ¥7.70 ¥8.04 ¥8.33 70
Growth Earnings
Growth-Adj P/E ¥11.12 ¥15.89 ¥20.66 65

Open the full fair value analysis →

Notify me when 688289 reaches fair value

Put 688289 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 54 · Market factors (momentum, volatility) 45

Profitability 28
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 19
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 65
Disciplined investing over empire-building
Low Volatility 78
Calm price path (market factor)
Momentum 36
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)
Net Issuance 85
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+13.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−35.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−38.3%
Dividend (yield on the price)3.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.65% → 12%

Watch 688289, get fair value alerts →

Compare Sansure Biotech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 55 · Below median
Fair Value upside −4% · Above median
Profitability
Return on equity (TTM) 2% · Below median
Return on assets 1% · Bottom 25%
Net margin (TTM) 10% · Above median
Operating margin (TTM) 12% · Above median
Growth and dividend
Revenue growth −8% · Bottom 25%
Dividend yield (TTM) 3.2% · Above median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 63.7× · Priciest 25%
P/B 1.34× · Cheaper than median
P/S (TTM) 6.02× · Priciest 25%
EV/EBITDA 21.4× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)28 · sector 15
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)6 · sector 25
HEALTH (low debt)93 · sector 96
DIVIDEND (yield)63 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.50 €158.95 +10%
Medline Inc MDLN $34.43 $30.15 −12%
Becton, Dickinson and Company BDX $183.00 $103.53 −43%
Alcon Inc ALC $65.59 $39.78 −39%
ResMed Inc RMD A$31.61 A$34.77 +10%
West Pharmaceutical Services, Inc WST $371.09 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €206.40 €54.82 −73%
Straumann Holding STMN CHF 97.86 CHF 45.50 −54%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sansure Biotech Inc · Fair Value
¥15.88 −4%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sansure Biotech Inc Fair Value". https://www.fairvalue-calculator.com/stock/688289

Frequently asked questions

Is Sansure Biotech Inc (688289) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥15.88 versus a price of ¥16.57, about −4% upside (fairly valued).
What is the fair value of 688289?
Our model-based fair value for Sansure Biotech Inc is ¥15.88 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥16.57.
What is the quality score of 688289?
Sansure Biotech Inc has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sansure Biotech Inc (688289)?
Our model-based price target is the fair value of ¥15.88 (as of Sep 24, 2026) from 17 valuation models. Cautious scenario ¥15.88, optimistic scenario ¥17.79. It is a calculation from audited fundamentals, not an analyst target.
What is the Sansure Biotech Inc stock forecast for 2026?
Our models put fair value at ¥15.88, about −4% upside versus a price of ¥16.57 (fairly valued). Cautious scenario ¥15.88, optimistic scenario ¥17.79. The calculation is refreshed regularly with new filings.
What is the revenue of Sansure Biotech Inc (688289)?
Sansure Biotech Inc reported trailing-twelve-month revenue of about 1.6B CNY (latest available figure, as of Sep 24, 2026).
Does Sansure Biotech Inc pay a dividend?
Sansure Biotech Inc currently shows a dividend yield of about 3.16% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Sansure Biotech Inc (688289)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sansure Biotech Inc it is ¥15.88 per share (as of Sep 24, 2026), against a price of ¥16.57. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Sansure Biotech Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 688289 trades above its calculated fair value: price ¥16.57, fair value ¥15.88, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688289?
No. The price is what the market pays today (¥16.57); the fair value is what the company's own numbers justify (¥15.88). For Sansure Biotech Inc the two are ¥0.6940 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sansure Biotech Inc worth?
The market values Sansure Biotech Inc at about 9.7B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥16.57; our models calculate a fair value of ¥15.88 per share.
What do the bullish and bearish scenarios say about 688289?
Our models span a range for Sansure Biotech Inc: cautious scenario ¥15.88, base ¥15.88, optimistic ¥17.79 per share (as of Sep 24, 2026, price ¥16.57). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688289?
Sansure Biotech Inc trades at a price-to-earnings ratio of 63.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥15.88 is built from several models across several years. Other multiples: P/B 1.3, P/S 6.0, EV/EBITDA 21.4.
How solid is the balance sheet of Sansure Biotech Inc (688289)?
Balance-sheet figures for Sansure Biotech Inc (as of Sep 24, 2026): return on equity 1.6%, debt of 0.13 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 688289 from its 52-week high?
Sansure Biotech Inc trades at ¥16.57, about 24% below its 52-week high of ¥21.70 and 19% above the low of ¥13.87 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥15.88 is for.
Which stocks are comparable to Sansure Biotech Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sansure Biotech Inc stock attractive at the current price?
The data as of Sep 24, 2026: price ¥16.57, calculated fair value ¥15.88 (−4%), Quality Score 55/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688289 calculated?
We run Sansure Biotech Inc through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥15.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Sansure Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sansure Biotech Inc (688289)?
The closing price on Sep 23, 2026 was ¥16.57. Our model-based fair value is ¥15.88, about −4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sansure Biotech Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (¥15.88 to ¥17.79), unusually little disagreement for a valuation.

Key figures of Sansure Biotech Inc

How large is the market capitalisation of Sansure Biotech Inc (688289)?
The market capitalisation of Sansure Biotech Inc is 9.7B CNY (≈ $1.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sansure Biotech Inc (688289)?
The price-to-sales ratio of Sansure Biotech Inc is 7.66 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sansure Biotech Inc (688289)?
Earnings per share at Sansure Biotech Inc are ¥0.2600 (price ÷ EPS = P/E 63.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sansure Biotech Inc (688289)?
The dividend yield of Sansure Biotech Inc is 3.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sansure Biotech Inc (688289)?
The net margin of Sansure Biotech Inc is 12.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sansure Biotech Inc (688289)?
The return on equity (ROE) of Sansure Biotech Inc is 1.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sansure Biotech Inc (688289)?
On an EBIT basis the return on assets of Sansure Biotech Inc is 14.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sansure Biotech Inc (688289)?
The operating margin of Sansure Biotech Inc is 12.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sansure Biotech Inc (688289)?
Revenue at Sansure Biotech Inc is growing −8.0% versus a year earlier (3y avg −36.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sansure Biotech Inc (688289)?
Earnings per share at Sansure Biotech Inc are growing −50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sansure Biotech Inc (688289) generate?
The free cash flow of Sansure Biotech Inc is −186M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sansure Biotech Inc (688289) hold?
Sansure Biotech Inc holds more cash than debt, 4.2B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sansure Biotech Inc in the live analysis

One click puts Sansure Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.